<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="45383">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02113826</url>
  </required_header>
  <id_info>
    <org_study_id>200240</org_study_id>
    <nct_id>NCT02113826</nct_id>
  </id_info>
  <brief_title>Pazopanib for Metastatic Alveolar Soft Part Sarcoma</brief_title>
  <official_title>A Phase II Trial of Pazopanib in Patients With Metastatic Alveolar Soft Part Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <authority>Korea: Ministry of Food and Drug Safety</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Alveolar soft part sarcoma (ASPS), a rare subset of STS (&lt;1%) harbors t(X;17)(p11;q25)
      translocation and produces resultant ASPL-TFE3 fusion protein. Due to its nature of high
      expression of angiogenic factors, sunitinib and cediranib produced overall response rates of
      55% and 43%, respectively. However, the efficacy of pazopanib is unknown in metastatic ASPS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pazopanib, a multi-targeted anti-angiogenesis inhibitor significantly prolonged
      progression-free survival (PFS) in patients with metastatic soft-tissue sarcoma (STS) after
      failure to anthracycline-based regimen (pazopanib vs placebo, 4.6 vs 1.6 months, HR=0.31,
      95% CI 0.24-0.40; P &lt; .0001). Regarding sunitinib (continuous daily dose of 37.5mg), after a
      median duration of 10 months, median OS and PFS were 19 months and 17 months, respectively
      in a small retrospective study (ASPS, N=9). With regard to cediranib, 6-month PFS was over
      60%. In addition, randomized phase II trial of sunitinib vs cediranib with cross-over at
      disease progression was recently initiated (NCT01391962). However, the efficacy of pazopanib
      is unknown in metastatic ASPS.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>One year</time_frame>
    <safety_issue>No</safety_issue>
    <description>ORR based on RECIST v1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>One year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety based on CTCAE v4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>6 month</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Two years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">19</enrollment>
  <condition>Metastatic Alveolar Soft Part Sarcoma</condition>
  <arm_group>
    <arm_group_label>Pazopanib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pazopanib 800mg po qd until disease progression</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pazopanib</intervention_name>
    <description>Pazopanib 800mg qd daily for 4 weeks = 1 cycle</description>
    <arm_group_label>Pazopanib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Histologically confirmed diagnosis of alveolar soft part sarcoma harboring TFE3
             fusion at stage IV or at relapse

          -  Age ≥ 18 years

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

          -  Measurable lesion defined by RECIST v1.1

          -  Chemo-naïve or prior chemotherapies

          -  Adequate organ function

        Exclusion Criteria:

          -  Prior malignancies

          -  Active CNS disease

          -  High-risk for gastrointestinal bleeding

          -  Significant cardiovascular disease

          -  Uncontrolled hypertension

          -  Bleeding diathesis
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tae Min Kim, MD, PhD</last_name>
    <phone>82-2-2072-3559</phone>
    <email>gabriel9@snu.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tae Min Kim, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Tae Min Kim, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 23, 2014</lastchanged_date>
  <firstreceived_date>April 9, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Tae Min Kim</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Pazopanib</keyword>
  <keyword>Alveolar soft part sarcoma</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sarcoma, Alveolar Soft Part</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
